

BALANCE-AAD-1 Study (IM045-P06)



A clinical study for the treatment of agitation in adults with Alzheimer's disease

Agitation is one of the most common features of Alzheimer's disease, occurring in up to 76% of people.¹ It can cause a person to become restless, engage in repetitive behaviors (eg, rocking), or even become verbally or physically aggressive (eg, shouting, pushing, resisting) in certain places or situations. These behaviors can significantly impact the quality of life for both the person with Alzheimer's disease and their caregivers.


If you or someone you know are experiencing agitation related to Alzheimer's disease, the BALANCE-ADD-1 Study may interest you. This study is testing an oral study drug to see if it can safely treat agitation.

The study is enrolling adults who*:


- Are 55 to 90 years of age.
- Have been diagnosed with Alzheimer's disease.
- Have had symptoms of agitation for at least 4 weeks.

*There are additional requirements to confirm your eligibility.

Participants will also need a study partner to come with them to visits and help with certain study activities. The study partner can be a staff member (nursing home or memory care facility), family member, friend, or hired caretaker.



What happens during the study? Participants may be in the study for up to 5.5 months.



The study drug and placebo are capsules (pills) that are **taken once a day**.

Participants will be closely monitored throughout the study for any changes in their health.

Participants will receive study-related drugs and have study-related visits and tests at no cost. Participants and caregivers/study partners may be reimbursed for time and travel. Speak to the study staff for more information.

Being in the study is voluntary. By taking part, you can help doctors better understand the study drug and Alzheimer's disease which may help others in the future.

For more information, please contact the study site.

Name Lauren McCall

Email lauren.mccall@cuanschultz.edu

Phone 720-507-9096

Thank you for considering the BALANCE-ADD-1 Study!

BMS - IM045-P06 - Participant Letter - 24-APR-2025- English (Principal) - V1.0
PIL-BALANCEAAD1

1. Jones E, Aigbogun MS, Pike J, et al. *J Alzheimers Dis.* 2021;83(1):89-101. doi:10.3233/JAD-210105

Celgene | Bristol Myers Squibb Company